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Abstract
The Ras GTPase-activating protein RasGAP catalyzes the conversion of active GTP-bound Ras into inactive GDP-bound Ras.
However, RasGAP also acts as a positive effector of Ras and exerts an anti-apoptotic activity that is independent of its GAP
function and that involves its SH3 (Src homology) domain. We used a combinatorial peptide aptamer approach to select a
collection of RasGAP SH3 specific ligands. We mapped the peptide aptamer binding sites by performing yeast two-hybrid
mating assays against a panel of RasGAP SH3 mutants. We examined the biological activity of a peptide aptamer targeting a
pocket delineated by residues D295/7, L313 and W317. This aptamer shows a caspase-independent cytotoxic activity on
tumor cell lines. It disrupts the interaction between RasGAP and Aurora B kinase. This work identifies the above-mentioned
pocket as an interesting therapeutic target to pursue and points its cognate peptide aptamer as a promising guide to
discover RasGAP small-molecule drug candidates.
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Introduction
The Ras signaling pathway plays a pivotal role in relaying
numerous extracellular signals to various intracellular regulatory
networks that control cell proliferation, differentiation and
apoptosis. Ras switches between an active (GTP-bound) and an
inactive (GDP-bound) state, which are produced by guanine
exchange factors such as Sos and GTPase-activating proteins
(GAP) such as RasGAP or neurofibromin, respectively [1].
Initially, RasGAP has been identified as the main negative
regulator of Ras, since its C-terminal GAP domain catalyzes the
hydrolysis of GTP-bound Ras to GDP-bound Ras. Subsequently, it
has been shown that the N-terminal region of this large protein is
essential to trigger downstream signals independently of its GAP
activity, and acts as a positive effector of Ras [2]. N-terminal
fragments of RasGAP, naturally generated by caspase cleavage,
exerteitherananti-apoptoticfunction(fragment N,1–455) ora pro-
apoptotic function (fragments N1, 1–157 and N2, 158–455) [3].
The N-terminal region of RasGAP (1–692) contains a pKC-
conserved region 2 (C2) domain, a pleckstrin homology (PH)
domain and a SH3 (Src Homology) domain flanked by two SH2
domains (Figure 1A). The SH2 domains mediate interactions with
phospho-tyrosine containing proteins such as PDGF-R, EGF-R, v-
Src, p62 and p190RhoGAP. The SH3 domain of RasGAP plays an
essential role in Ras downstream signaling [2] and influences Rho-
mediated cytoskeleton reorganization, independently from Ras [4].
The microinjection of a monoclonal antibody directed against
RasGAP SH3 was shown to induce apoptosis in tumor cells but not
in non-transformed cells [5]. A few RasGAP SH3-interacting
proteins have been discovered so far. First studies have identified a
GAP SH3-Binding Protein (G3BP) [6] and an unknown 14 kDa
protein [7]. More recently, Aurora kinases have been shown to bind
to RasGAP SH3 [8] and these interactions are suspected to play a
crucial role in the Ras effector activity of RasGAP in cancer cells.
We reasoned that the use of specific peptidic ligands would
enable a better mechanistic understanding of the role of RasGAP
SH3 and of its interaction with Aurora kinases in Ras downstream
signaling. The usual strategies to discover SH3 domain-targeting
molecules appear ill-suited to RasGAP SH3, since this atypical
domain has not been shown to interact with proline-rich
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2902sequences, which is a common feature of SH3 domains. An
alternative approach was thus required.
Peptide aptamers are combinatorial recognition molecules that
consist of a constant scaffold protein displaying a doubly-
constrained variable peptidic region [9]. They bind to intracellular
proteins with a high specificity and a strong affinity, and can thus
modulate the function of their targets [10]. Their unbiased
combinatorial nature allows interrogating the biological signifi-
cance of numerous molecular surfaces on their cognate target
proteins. The use of peptide aptamers can guide the discovery of
small molecules targeting those molecular surfaces that are
biologically validated and druggable [11].
Here, we report the selection and characterization of peptide
aptamers that bind specifically to RasGAP SH3. One of these
aptamers disrupts the interaction between RasGAP and Aurora B
and induces caspase-independent tumor cell death.
Results
Selection of RasGAP SH3-interacting peptide aptamers
We used an improved yeast two-hybrid method and a new
generation peptide aptamer library [12] to select peptide aptamers for
their ability to bind to RasGAP SH3. We obtained 14 different
peptide aptamers, whose binding specificity was determined using a
yeast two-hybrid mating assay. As shown in Figure 1C, except for
RG22 and RG24, no aptamer interacted with Nck or Grb2, two
proteins containing respectively three and two SH3 domains that
show sequence similarity with RasGAP SH3 (Figure 1B). RG22 and
RG24 are two LexA-interacting aptamers, which exhibit an
interaction phenotype with most LexA fusion proteins (albeit not
with the LexA-Cdk2 control). Hence, we obtained 12 different
peptide aptamers that interact specifically with RasGAP SH3. Except
for RG18 and 25, all of them showed a comparable or weaker
Figure 1. RasGAP SH3 peptide aptamer binding specificity. (A) Protein domain mapping of the RasGAP protein. PPP: Proline-rich region; PH:
Pleckstrin homology domain; C2: pKC-conserved region 2. (B) Sequence alignment of RasGAP, Nck, and Grb2 SH3 domains. Residues that are
conserved between at least two proteins are highlighted in green. (C) Yeast two-hybrid interaction mating assay. LexA fusion proteins (‘‘baits’’) were
expressed in EGY191a yeast containing a 8 lexAop-lacZ reporter gene. Control and selected peptide aptamers (fused to the B112 activation domain)
were expressed in EGY42a yeast. Strains were mated and diploids were grown on X-gal-containing solid medium. 10M is a Cdk2 peptide aptamer and
Control is a peptide aptamer randomly picked from the library.
doi:10.1371/journal.pone.0002902.g001
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None of them showed an interaction phenotype with the full length
RasGAP bait construct, whose apparent expression level in yeast was
comparableto that of the other bait proteins presently used, as judged
from the interaction phenotypes observed with the anti-LexA
aptamers RG22 and RG24 (Figure 1C).
To confirm some of the yeast two-hybrid phenotypes, we
performed pull-down experiments using 6 GST-RasGAP aptamer
fusion proteins and recombinant purified 6xHis-RasGAP SH3. We
confirmed the binding between RasGAP SH3 and all 6 peptide
aptamers tested, with highlyvariableapparent bindingaffinities that
were not determined by the amounts of GST-aptamer fusion
proteins coupled to glutathione-sepharose beads and that did not
matchtheintensitiesoftheyeast two-hybrid phenotypesobserved in
the yeast two-hybrid mating assay (Figure 2).
Mapping of the RasGAP SH3 peptide aptamer binding
sites
We performed an AptaPrint assay to map the peptide aptamer
binding sites on the RasGAP SH3 domain [11,12]. Based on the
NMR structure [13], we created 11 mutants to interrogate different
molecular surfaces (Figure 3A). As shown in Figure 3B, our peptide
aptamer collection showed different binding profiles against the
RasGAP SH3 mutant panel, thus indicating that the aptamers bind
to their target on different molecular surfaces. All aptamers (except
RG28 and RG30) showed a decreased or abolished interaction
phenotype against the W317K mutant, which suggests that this
residue contributes to the integrity of most aptamer binding surfaces.
Most aptamers (RG17, 18, 20, 21, 23, 26, 27, 29) failed to show an
interaction phenotype when either L313 or D295/7 were mutated,
which suggests that they bind to the pocket delineated by W317 and
these three residues (Figure 3B and C). However, RG19 and RG25
seem to bind to a different surface as they retained their interaction
phenotypes, either with the D295/7A and the L313A mutants
(RG19), or with the D295/7A mutant (RG25). This AptaPrint did
not provide information on the binding sites of RG28 and 30, since
both aptamers retained their interaction phenotypes with all mutants.
Peptide aptamer interactions in a mammalian cell
context
We set out to determine the ability of the peptide aptamers to
bind to the full length RasGAP protein in mammalian cells. To
this end, we performed two-hybrid assays in HeLa cells that
expressed a full-length RasGAP bait protein and all the selected
aptamers, as preys. We failed to detect any significant interaction
signal (data not shown). We performed the same experiments using a
RasGAP SH3 bait protein. RG27 was the only peptide aptamer
that strongly interacted with RasGAP SH3 in this assay
(Figure 4A). We then performed a pull-down experiment using a
GST-RG27 fusion protein and a mouse liver total protein extract.
We successfully captured the native endogenous RasGAP protein
from the extract using the GST-RG27 fusion but not a GST-
control aptamer fusion (Figure 4B). From all these observations,
we conclude that aptamer RG27, at least, can interact with the
native RasGAP protein in a mammalian cell context and that the
lack of two-hybrid interaction phenotypes between the peptide
aptamers and the full length RasGAP bait proteins is probably
caused by an improper folding of the RasGAP moiety or, more
probably, by a masking of the SH3 domain when the entire
protein is expressed in yeast or human cell nuclei (see Discussion).
Peptide aptamer cytotoxic activity
We examined the ability of RG27 to inhibit tumor cell growth.
We first performed colony formation assays on HeLa, HCT116
and Panc 10.05 cells, derived from cervix, colon and head-of-
pancreas adenocarcinomas, respectively. HCT116 and Panc 10.05
cells bear a Ras oncogenic mutation. We stably expressed for two
weeks a control aptamer (C6) or RG27. In all three cell lines,
RG27 showed a growth inhibitory activity, in contrast with C6
that was inactive (Figure 5A and B).
We then examined whether this inhibition of tumor cell growth
was caused by an induction of cell death. We transiently expressed
C6 or RG27 in the same cell lines as above. We evaluated cell
viability at different times after transfection by performing a trypan
blue exclusion test. In accordance with the results of the colony
formation assays, RG27 but not C6 induced a marked decrease of
the viability of tumor cell lines. Importantly, RG27 expression did
not affect the viability of normal primary fibroblasts (Figure 6A).
To further characterize RG27-induced cell death, we performed
an Annexin V/propidium iodide double-labeling on the three
tumor cell lines and on the untransformed fibroblasts. Consistent
with the trypan blue exclusion test, RG27 but not C6 caused a
significant increase in tumor cells labeled positively with these cell
death markers, and remained inactive in untransformed fibroblasts
(Figure 6B). We also examined the nuclei of HeLa cells expressing
our peptide aptamers. In contrast to the nuclei of untransfected
cells or of C6-expressing cells, the nuclei of cells expressing RG27
appeared clearly fragmented (Figure 7).
Mechanism of action of cytotoxic peptide aptamer
To determine whether RG27-induced cell death involved
caspases, we performed an Annexin V/propidium iodide dou-
Figure 2. in vitro binding of peptide aptamers to RasGAP SH3. Pull-down assay with recombinant purified RasGAP SH3. Recombinant purified
6xHis-RasGAP SH3 was added to GST-peptide aptamer fusion proteins, coupled to glutathion-sepharose beads. ‘‘Control’’ is a peptide aptamer that
was selected against another target protein. Captured protein was revealed with an anti-His antibody. GST-aptamer fusions coupled to beads were
stained with Coomassie blue.
doi:10.1371/journal.pone.0002902.g002
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of the pan-caspase inhibitor Z-VAD-fmk [14]. As shown in
Figure 8A, cell death induced by RG27 was not affected by Z-
VAD-fmk, which inhibited Staurosporine-induced cell death, as
expected (Figure 8B). In accordance with this result, we observed
that RG27-expressing cells did not exhibit significant caspase 3, 8
and 9 activities, which could be detected upon Staurosporine
treatment (Figure 8C). We also failed to detect active caspases in
RG27-expressing cells (Figure 8D). Altogether, these observations
establish that RG27 induces caspase-independent tumor cell
death.
We wondered whether RG27-induced cell death involved
members of RasGAP SH3 interaction complexes suspected to
play an important role in Ras downstream signaling [8]. We thus
performed similar experiments on HeLa cells that we co-
transfected with either C6- or RG27-expression plasmids and
siRNAs against Aurora A, Aurora B, or Survivin. We first
determined the efficacy of our Aurora siRNAs. As shown in
Figure 9A, Aurora A and Aurora B siRNAs caused a comparable,
partial expression knockdown of their cognate targets. Whereas
Aurora A siRNAs did not affect RG27-induced cell death (as
compared to a scrambled siRNA or no siRNA), Survivin siRNAs
and even more so Aurora B siRNAs enhanced the cell death
observed in RG27-expressing cells. This enhancement was caused
by a potentiation of RG27 cytotoxic activity rather than by a
simple additive phenomenon, since none of the tested siRNAs
affected the basal cell death level observed in C6-expressing cells
(Figure 9B).
To further explore the mechanism of action of RG27, we
examined the ability of this peptide aptamer to inhibit the
interaction between RasGAP and Aurora B [8]. Using a RasGAP
SH2-interacting peptide coupled to CNBr-sepharose beads, we
performed a RasGAP pull-down assay from HeLa, HCT116 and
Panc 10.05 cells expressing either the control peptide aptamer (C6)
or RG27. As shown in Figure 10(A,B,C) we were unable to
capture significant levels of Aurora B associated to RasGAP in
RG27-expressing cells, in contrast to C6-expressing cells. This
result was not caused by lowered expression levels of RasGAP or
Aurora B in RG27-expressing cells. Interestingly, the amount of
RasGAP captured from cells expressing RG27 was lower than that
captured from cells expressing a control aptamer. This may be due
to a steric hindrance caused by RG27 binding to the SH3 domain,
which is situated just between the two SH2 domains that are
bound by the Dok-derived peptide (Figure 1A).
Figure 3. Mapping of the peptide aptamer binding sites on RasGAP SH3 by AptaPrint. (A) RasGAP SH3 aminoacid substitutions. (B)
AptaPrint assay. 11 LexA fusions with RasGAP SH3 mutants were expressed in EGY48a yeast containing a 8 lexAop-lacZ reporter gene. Peptide
aptamer-B112 fusions were expressed in EGY42a yeast. A yeast two-hybrid mating assay was performed. (C) NMR structure of the RasGAP SH3
domain. Residues W317, L313 and D295/7 are located.
doi:10.1371/journal.pone.0002902.g003
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with a plasmid directing the expression of a GAL4-RasGAP SH3 bait protein, a plasmid containing a luciferase two-hybrid reporter gene, and plasmids
directing the expression of VP16-peptide aptamer fusions. Luminescence was measured 48 h after transfection. Two independent experiments were
performed. SH3-pACT: RasGAP bait with empty prey plasmid; pBIND-pACT: empty bait and prey plasmids; Control-pACT: empty prey plasmid only. (B)
Pull-down assay from total protein extract. Left: A mouse liver total protein extract was added to glutathion sepharose beads, uncoated (2) or coated
with GST-RG27 or GST-Control fusion proteins. Captured native RasGAP protein was revealed with a monoclonal antibody directed against the SH3
domain. Right: Coomassie staining of a SDS-PAGE revealing comparable amounts of GST-Control and GST-RG27 fusion proteins immobilized on
glutathion sepharose beads.
doi:10.1371/journal.pone.0002902.g004
Figure 5. Cell growth inhibitory activity of RG27 peptide aptamer. (A) Colony formation assays. A control peptide aptamer or RG27 were
stably expressed for two weeks in HeLa, HCT116 or Panc 10.05 cells. Cells were stained with crystal violet. (B) Quantification of results shown in (a) and
in two other experiments **: p value ,0.01.
doi:10.1371/journal.pone.0002902.g005
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different cell lines. We next examined the impact of this disruption
on the kinase activity of Aurora B. To this end, we measured the
phosphorylation levels of histone H3, a well-described substrate of
Aurora B [15]. HeLa cells expressing RG27 showed a markedly
decreased content in phosphorylated histone H3 as compared to
C6-expressing cells (Figure 10D). This result indicates that RG27
expression induces a strong inhibition of Aurora B kinase activity.
Discussion
We have used an improved peptide aptamer yeast two-hybrid
method to select combinatorial peptidic ligands that interact
specifically with RasGAP SH3. The sequence analysis of the
peptide aptamer variable regions did not reveal any significant
homology with naturally occurring proteins (Table 1). Interesting-
ly, only one of the selected aptamers (RG26) harbored a variable
region that contained a PxxP motif. Although more experiments
would be needed to establish whether this motif mediates the
interaction with RasGAP SH3, the fact that 11 out of the 12
selected peptide aptamers do not contain proline-rich variable
regions validates our choice of a combinatorial approach to obtain
peptidic ligands against this atypical SH3 domain.
None of the selected aptamers showed a two-hybrid interaction
phenotype with a full-length RasGAP bait protein either in yeast or in
HeLa cells. This result could be accounted for by the previously
proposed masking of the SH3 domain by the two flanking SH2
domains, which, in absence of tyrosine-phosphorylated interacting
Figure 6. Cytotoxic activity of RG27 peptide aptamer. (A) Trypan blue exclusion assay. Control peptide aptamer (C6) and RG27 were
transiently expressed in untransformed fibroblasts or in HeLa, HCT116 or Panc 10.05 tumor cell lines. The percentage of cells that excluded trypan
blue was determined at different times after transfection. (B) Propidium iodide/Annexin V labeling assay. The percentage of cells that incorporated
propidium iodide and that were positively labeled with Annexin V was determined by flow cytometry 36 h post-transfection for HeLa cells and 48 h
post-transfection for HCT116 cells, Panc 10.05 cells and untransformed fibroblasts. Three independent experiments were performed in all assays. **: p
value ,0.01. Transfection rates were 75% for HeLa cells, 55% for HCT116, 40% for Panc 10.05 cells, and 70% for untransformed fibroblasts.
doi:10.1371/journal.pone.0002902.g006
Figure 7. Nuclear fragmentation of RG27-expressing cells. The
nuclei of HeLa cells untransfected or transfected with control aptamer
or RG27 expression plasmids were labeled by DAPI 36 h post-
transfection and observed using an epifluorescence microscope.
doi:10.1371/journal.pone.0002902.g007
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domain in the context of the full-length RasGAP protein only, but not
in the context of a SH2-SH3-SH2 construct [7]. Yeast is known,
indeed, to contain very few tyrosine kinases, and it is conceivable that
the RasGAP SH2 tyrosine-phosphorylated interacting partners are
absent from human cell nuclei or present in too little amounts. The
fact that a RasGAP SH3 peptide aptamer affinity matrix could
readily pull-down native RasGAP from a total protein extract
supports the hypothesis of the masking of the SH3domain in the two-
hybrid setting. Surprisingly, RG27 was the only peptide aptamer that
produced a strong two-hybrid interaction phenotype in HeLa cells.
The weak or absent interaction phenotypes produced by all other
peptide aptamers could be due to their lower steady-state expression
levels and/or to the lower sensitivity of this assay as compared to the
yeast assay.
The mapping of the peptide aptamer binding sites on RasGAP
SH3 revealed different interesting facts. First, several molecular
surfaces are targeted by this pool of 12 selected aptamers, as
judged from the different profiles of yeast two-hybrid interaction
phenotypes in the AptaPrint assay. Although the ability of large
collections of peptide aptamers to ‘‘decorate’’ many surfaces on
their cognate protein targets is constantly observed [11], it is
striking that this holds true for a mid-sized collection of aptamers
interacting with a small 60 aminoacid protein domain. Second,
most peptide aptamers showed a decreased or abolished two-
hybrid interaction phenotype with the RasGAP SH3 W317K
mutant. Taken alone, this observation does not necessarily mean
that most peptide aptamers establish a direct contact with W317.
Indeed, since W317 seals together two spatially neighboring loops,
the W317K mutation may induce long-range conformational
changes on the SH3 domain. However, most peptide aptamers
that showed a decreased or abolished interaction phenotype with
the W317K mutant showed also a decreased or abolished
interaction phenotype with the D295/297A and the L313A
mutants. This observation strongly suggests that most peptide
aptamers bind the pocket delineated by residues D295/7, L313
and W317, which may constitute a protein interaction hotspot.
We examined the bioactivity of RG27, an aptamer that targets
the above-mentioned pocket, interacts with RasGAP SH3 in a
HeLa cell two-hybrid assay, and interacts with the native full
length RasGAP protein in a pull-down assay. In contrast to the C6
control, RG27 showed a marked cytotoxic activity when expressed
in HeLa, HCT116 or Panc 10.05 tumor cell lines but not in
normal primary fibroblasts. The lack of activity of RG27 in the
latter cells is not due to a longer doubling time as compared to that
of tumor cells (19–20 h for untransformed fibroblasts, Panc 10.05
and HCT116 cells; 16 h for HeLa cells). RG27-induced cell death
is not inhibitable by the Z-VAD-fmk pan-caspase inhibitor, does
not involve caspase 3, 8 and 9 activity, and can thus be qualified as
caspase-independent cell death [14].
Among the few proteins known to form interaction complexes
with the SH3 domain of RasGAP, Aurora kinases and Survivin
Figure 8. Caspase involvement in RG27-induced cell death. (A) Propidium iodide/Annexin V labeling assay in presence of caspase inibitor. The
percentage of HeLa cells (transfected with control aptamer or RG27 expression plasmids) that incorporated propidium iodide and that were positively
labeled with Annexin V was determined by flow cytometry 36 h post-transfection in presence or in absence of 50 mM pan-caspase inhibitor Z-VAD-
fmk. (B) Same experiment as in (A), on HeLa cells treated with 0.1 mM Staurosporine for 36 h. (C) Caspase activity assays. Caspase 3, 8, 9 activities were
measured by flow-cytometry in HeLa cells 36 h post-transfection or after 36 h of treatment with 0.1 mM Staurosporine. Values are expressed as ‘‘fold
induction’’, as compared to basal caspase activity values measured in non-transfected, untreated cells (D) Detection of active caspases. Western blots
were performed from HeLa cell extracts obtained 36 h after transfection or treatment with 0.1 mM Staurosporine, using antibodies directed against
active caspases. NT: non-transfected; Cont: control peptide aptamer.
doi:10.1371/journal.pone.0002902.g008
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regulation of multiple cell cycle steps, in cell survival and in
tumorigenesis [16,17]. We showed that RG27-induced cell death
was slightly potentiated by siRNAs directed against Survivin and,
to a larger extent, by siRNAs directed against Aurora B. The lack
of a detectable cytotoxic effect of our siRNAs on C6-expressing
cells can be explained by their partial efficacy in knocking-down
the expression of their cognate proteins and, in any case, by the
fact that protein expression knockdown and protein targeting by
specific ligands introduce different perturbations within regulatory
networks, which give rise to different phenotypic responses [18].
These results suggested that RG27 might exert its cytotoxic
activity by disrupting RasGAP-Aurora B interactions.
We showed that RasGAP-Aurora B complexes could not be
detected in HeLa, HCT116 or Panc 10.05 cells expressing RG27.
This peptide aptamer may disrupt RasGAP-Aurora complexes by
competing directly with Aurora for binding to the SH3 domain of
RasGAP. The lack of interaction between Aurora and a RasGAP
W317K mutant supports this hypothesis [8]. Another disruption
mechanism may involve an aptamer-mediated sequestration of
RasGAP into aggresomes, according to a recently described
phenomenon observed with the hepatitis B virus core protein and
the human papillomavirus E6 protein [19]. However, several
arguments speak against this hypothesis. First, we have performed
immunofluorescence experiments in RG27-EGFP- expressing cells
and we have not observed any perinuclear co-localization of
RasGAP and RG27 (data not shown), where aggresomes are located
[19]. Second, the new-generation peptide aptamers presently used
contain shorter variable regions (13 aminoacids instead of 20),
which greatly enhances the average solubility level of recombinant
purified aptamers. We would also expect an improved average
solubility level of such peptide aptamers expressed in human cells.
Third, we expressed untagged peptide aptamers in our cellular
assays, which contrasts with the expression of much larger 6xHis-
aptamer-VP22 fusion proteins by Tomai et al. (2006), which may
be more prone to aggregation.
RG27-induced tumor cell death could be caused, at least in
part, by the disruption of the interaction between RasGAP and the
Aurora B-Survivin complex, and by the subsequent inhibition of
Aurora B kinase activity. The antiproliferative and antitumoral
properties of Aurora small molecule inhibitors are indeed well
described [20,21]. Since Aurora kinase activity was shown to be
inhibited by the interaction with RasGAP in COS cells
overexpressing Aurora [8], the inhibition observed in RG27-
expressing cells might not be a direct consequence of the
disruption of RasGAP-Aurora complexes and could be caused
by a downstream event. Importantly, we cannot rule out that
RG27-induced cell death is (also) caused by the disruption of
another protein interaction that involves the SH3 domain of
RasGAP. Our results are in line with the recent observation that a
RasGAP SH3-derived minimal peptidic sequence sensitized tumor
cell lines to a variety of cytotoxic molecules [22]. Although the
mechanism of action of this peptide remains to be determined, it is
likely to reside in the titration of RasGAP SH3 interacting partners
(Aurora or another protein).
Ras is found mutated and/or deregulated in more than 30% of
human cancers, and is thus considered as a highly interesting
target to pursue for developing novel cancer therapies [23].
However, no Ras-targeting therapeutic molecule has passed
clinical trials successfully up to date. The high intracellular
Figure 9. Aurora kinase and Survivin involvement in RG27-induced cell death. (A) Silencing of Aurora A and B expression. HeLa cells were
transfected with scrambled (Scr) siRNAs or with siRNAs directed against Aurora A or B (Cont: untransfected cells). Aurora A and B expression was
revealed by Western blot experiments using specific antibodies, and c-tubulin expression was used as a control (B) HeLa cells were co-transfected
with a plasmid directing the expression of either control aptamer C6 or RG27, and with siRNAs directed against Aurora A, Aurora B, or Survivin
(‘‘Untreated’’: no siRNA; ‘‘Scr’’: scrambled siRNA). Cells were labeled and analyzed as in Figure 6B.
doi:10.1371/journal.pone.0002902.g009
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numerous small G-proteins makes it difficult to discover Ras
selective, potent inhibitors targeting the GTP-binding pocket.
Farnesyl transferase inhibitors, which inhibit Ras function by
preventing its translocation to the plasma membrane, have shown
disappointing efficacy in clinical trials [24]. Molecules that disrupt
protein interactions involving Ras are promising but still at early
development stages [25]. An alternative Ras-targeting strategy
consists of modulating the activity of the proteins that control the
balance between the active and inactive forms of Ras, or that act
as positive effectors of Ras. A seminal work using a monoclonal
antibody against RasGAP SH3 has demonstrated that this domain
was a potentially interesting target to pursue [5]. Our work further
validates RasGAP SH3 (and more precisely the pocket delineated
by residues D295/7, L313 and W317) as a promising therapeutic
target in oncology. It points RG27 as a useful guide for the
discovery of small molecule ligands against this target. To this end,
we are now following two complementary approaches. First,
ongoing NMR structural studies of complexes formed between
RasGAP SH3 and RG27 or RG27-derived synthetic peptides will
unveil precisely the molecular surface bound by the aptamer. This
information may enable a structure-based drug design effort to
obtain small molecule ligands to this surface. In parallel, high-
throughput ‘‘AptaScreen’’ assays are performed to identify small
molecules that disrupt the interaction between RasGAP SH3 and
RG27 [11]. This dual strategy may yield promising small-molecule
drug candidates.
Figure 10. RG27-induced inhibition of RasGAP-Aurora B interaction and of Aurora B kinase activity. (A,B,C) RasGAP/Aurora B co-capture
assay. Upper panels: A RasGAP pulldown assay was performed from HeLa cells (A), HCT116 cells (B) and Panc 10.05 cells (C) expressing control
aptamer C6 or RG27, using either a RasGAP-SH2-interacting peptide (DOK) coupled to CNBr-sepharose beads or uncoupled beads (Cont.). Captured
RasGAP and Aurora B proteins were revealed by Western blotting. Lower panels: Western blot experiments were performed from a fraction of the
total HeLa, HCT116, and Panc 10.05 cell lysates used in the pulldown assays, and from lysates of non-transfected cells (NT), using RasGAP and Aurora
B specific antibodies. (D) Aurora B kinase activity. The content of phosphorylated Histone H3 was determined by Western blot from soluble protein
extracts of HeLa cells expressing either C6 or RG27 peptide aptamers. A Western blot using a c-tubulin antibody was performed to obtain a loading
control. Histogram shows the quantification of three independent experiments.
doi:10.1371/journal.pone.0002902.g010
Table 1. RasGAP SH3 peptide aptamer sequences
Peptide Aptamers Sequences of variable regions
RG17 WYIRGKWVTGGRS
RG18 VWLACNRVCGSRG
RG19 TMHEKVWSPINSF
RG20 QHLTRGSPEFYHV
RG21 RNPNGCMPRYYHR
RG23 RPAKSACPTHPHL
RG25 CTWSYNAQGRIWV
RG26 ASTFPKPPRFYHV
RG27 KWVVSHARLMYSF
RG28 EGACPWEVRRLRF
RG29 RRLSRMCPSRYFT
RG30 GVAPWGTTTCRRF
doi:10.1371/journal.pone.0002902.t001
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Plasmid constructions
Bait plasmids. We amplified RasGAP SH3 (wild type and
W317K mutant) coding sequences from existing plasmids [8] using
oligonucleotides 59-ATATGAATTCGGCGGTGAAGATAGA-
AGGCGTGTACG -39 and 59-TAATGGATCCTTATATT-
TTTCCTTCATGTGGATCTTC-39 that contained an EcoRI
and a BamHI site, respectively. We ligated the PCR product into
EcoRI/BamHI-cut pEG202. We amplified the RasGAP SH2/3/2
coding sequence using oligonucleotides 59-ATA TGAAT-
TCGGTGGCGCCATACCGTTGACCGCTCCTCC-39 and
59- TAAT GTCGACCTATTGTTCTTGATCCTGCATTGG-
TAC-39 that contained an EcoRI and a SalI site, respectively. We
ligated the PCR product into EcoRI/XhoI-cut pEG202.
To perform mutagenesis on RasGAP SH3, we used the following
oligonucleotides: R281A-sens: 59-GTGAAGATGCAAGGCGTG-
TACGAGCTATTCTACC-39 R281A-rev: 59-CTCGTACACG-
CCTTGCATCTTCACCGCCGAATTCCAG-39; R282A-sens:
59-GGTGAAGATAGAGCGCGTGTACGAGCTATTCTACC-
39; R282A-rev: 59-CTCGTACACGCGCTCTATCTTCA-
CCGCCGAATTCC-39; D295/7A-sens: 59-GCTATTCTACCT-
TACACTAAAGTACCAGCCACTGCTGAAATAAGTTTC-39;
D295/7A-rev: 59-CATATCTCCTTTTAAGAAACTTATTTC-
AGCAGTGGCTGGTAC-39; L313A-sens: 59-GTTCATAAT-
GAAGCAGAAGATGGATGGATGTGGGTTAC-39; L313A-
rev: 59-CCATCCATCTTCTGCTTCATTATGAACAATGAA-
CATATCTCC-39; E333A-sens: 59-CCTTATTGTTGCAGACC-
TAGTAGAAGAGGTGGG-39; E333A-rev: 59-CTCTTCTAC-
TAGGTCTGCAACAATAAGGCCTTGTTCATCTGTTC-39;
E338A-sens: 59-CTAGTAGAAGCGGTGGGCCGGGAAGAA-
GATC-39; E338A-rev: 59-GGCCCACCGCTTCTACTAGGTC-
TTCAACAATAAGGC-39; E341A-sens: 59-GGTGGGCGCG-
GAAGAAGATCCACATGAAGG-39; E341A-rev: 59-GATCT-
TCTTCCGCGCCCACCTCTTCTACTAGG-39; E343A-sens:
59-GCCGGGAAGCAGATCCACATGAAGGAAAAATATAAG-
G-39; E343A-rev: 59-CATGTGGATCTGCTTCCCGGCC-
CACCTC-39; H346A-sens: 59-GGAAGAAGATCCAGCTGAA-
GGAAAAATATAAGGATCCGTCGACC-39; H346A-rev: 59-
CCTTATATTTTTCCTTCAGCTGGATCTTCTTCCCGG-
CC-39; E347A-sens: 59-GATCCACATGCAGGAAAAATA-
TAAGGATCCGTCGACC-39; E347A-rev: 59-GATCC TTA-
TATTTTTCCTGCATGTGGATCTTCTTCCCGG-39. For
each mutation, we performed two amplifications of the RasGAP
SH3 coding sequence from the pEG202 construct, using on the one
hand the cognate ‘‘sens’’ oligonucleotide and 59- GTTGCCA-
GAAAATAGCGAGTTTAAACC-39, and on the other hand the
cognate ‘‘rev’’ oligonucleotide and 59-GGAAAGAGTTACTCAA-
GAACAAGAATTTTCG-39. We purified the PCR products and
paired them according to their cognate mutant. We then performed
a PCR amplification on each mix, adding at the end of the seventh
cycle the oligonucleotides 59-GTTGCCAGA AAATAGC-
GAGTTTAAACC-39 and 59-GGAAAGAGTTACTCAAGAA-
CAAGAATTTTCG-39. We co-transformed EGY48a yeast with
the PCR products and EcoRI/XhoI-cut pEG202 to clone the
RasGAP SH3 mutants by gap repair. We retrieved the plasmids by
yeast DNA minipreps, transformed them into E.coli, and verified the
mutations by sequencing.
Bacterial expression plasmids. We amplified peptide
aptamer coding sequences from the library plasmids using the
oligonucleotides 59- CCACTTTAACTAATACTTTCAACATT-
TTCGG-39 that hybridized to the GAL promoter and 59-TG-
GGAACTCCTCGAGCTAGGCCAGGTTGGCGTCC-39 that
hybridized to the 39 end of thioredoxin and that contained a stop
codon. We ligated the PCR productsinto EcoRI/XhoI-cutpGEX4T1
(GE Healthcare).
Mammalian cell two-hybrid plasmids. We amplified the
aptamer coding sequences from the library plasmids using the
oligonucleotides 59-TTATAGGATCCCTCGAGTTATGAGC-
GACAAGATCATCCACC-39 and 59-TGTCTGCTCGAAGC-
GGCCGCGGCTAGGCCAGGTTGGCGTCCAGGAACTCC-
39 that contained a XhoI and a NotI site, respectively. We ligated
the PCR products into SalI/NotI-cut pACT, a plasmid directing
the expression of proteins fused to the VP16 activation domain
(Promega). We amplified the RasGAP SH3 coding sequence from
the pEG202 construct using the oligonucleotides 59-TAAATA
TAATGGATCCGCGACTGGCTGGAATTC-39, which con-
tained a BamHI site, and 59-GGAAAGAGTTACTCAAGA-
ACAAGAATTTTCG-39. We ligated the PCR product into
BamHI/NotI-cut pBIND, a plasmid directing the expression of
proteins fused to the GAL4 DNA binding domain and the
expression of a Renilla luciferase transfection marker (Promega).
Mammalian cell expression plasmids. We amplified the
RG27 and the control aptamer coding sequences from the library
plasmids using the oligonucleotides 59-ATTCTAGCCTCG-
AGGAATTCACCATGAGCGACAAGATCATCC-39and 59-T -
GTCTGCTCGAAGCGGCCGCGGCTAGGCCAGGTTGG-
CGTCCAGGAACTCC-39, that contained a XhoI and a NotI site,
respectively. We ligated the PCR products into XhoI/NotI-cut
pPER, a pCEP4-derived episomal vector that bears a CMV
promoter and a hygromycin selection marker.
siRNA sequences
Aurora A: 59-AAAUGCCCUGUCUUACUGUCA-39; Aurora
B: 59- AAGGUGAUGGAGAAUAGCAGU-39; Survivin: 59-
AAGGCUGGGAGCCAGAUGACG-39; Scrambled control: 59-
CAUGUCAUGUUCACAUCUCTT-39. siRNAs were purchased
from Sigma Proligo.
Yeast two-hybrid selection of peptide aptamers
The selection was performed as described [12], using the yeast
strains MB210/MB226 and the ACC02.2 peptide aptamer library
[18]. We transformed MB210 with ACC02.2 and we obtained
2.8610
7 transformants. We transformed MB226 with pEG202-
RasGAPSH3 and pSH18-34. We estimated the mating efficiency
of MB210 at 84.6% and the number of diploid exconjugants at
3.3610
8. We plated 3.3610
7 diploids onto 2069 cm plates with
galactose/raffinose selective medium and incubated for 5 days. We
replica-plated onto 20 X-gal galactose/raffinose medium. We
picked 26 clones that grew in absence of leucine and adenine and
that displayed a b-galactosidase activity. Library plasmids were
recovered and re-transformed into EGY42a. The interaction
phenotypes were confirmed by a mating assay with EGY191a
transformed with pEG202-RasGAP SH3 and pSH18-34.
Yeast two-hybrid interaction mating assays
The binding specificity and the AptaPrint assays were
performed as described [12].
Pull-down assays
RasGAP-aptamer interactions. We transformed pGEX4T1-
aptamer plasmids into E.coli BL21 (DE3). We induced the expression
of the GST-aptamer fusions with 1 mM IPTG at 20uCo v e r n i g h t .
We collected the bacteria and resuspended them into lysis buffer I
( 5 0m MT r i sp H 8 ,0 . 1MN a C l ,1m MD T T )c o n t a i n i n g1m g / m L
lysozyme. We froze and thawed the suspensions three times and
sonicated on ice. We centrifuged the lysates at 13 000 g for 30 min,
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to verify that the respective amounts of GST-aptamer fusions were
comparable. We thus immobilized equal amounts of GST-aptamer
fusions on 100 mL glutathion sepharose 4B (GE Healthcare) at room
temperature for 1 h. We washed the beads five times with 1 mL of
lysis buffer.
We transformed pT7-7-RasGAP SH3 plasmid into E.coli C41
(DE3). We induced the expression of the 6xHis-RasGAP SH3
fusion with 1 mM IPTG at 20uC overnight. We prepared a soluble
protein extract as described above. We purified the fusion protein
using a Ni-NTA solid phase (Qiagen) according to the instructions
of the manufacturer. To prepare a mouse liver total protein
extract, we cut half a liver in small pieces to which we added
500 mL of lysis buffer II (40 mM Tris-HCl pH8, 500 mM NaCl,
1x Triton, 1 mM DTT, 15 mM EGTA, 1 mM Na3VO4, and a
Roche protease inhibitor coktail). We lysed the liver pieces with
Fast Prep glass beads, running 2 cycles of 20 seconds in a FastPrep
FP120 cell disrupter (Qbiogene). We centrifuged the lysate at
13000 g for 30 min at 4uC, collected the supernatant, and
determined protein concentration using a Bradford assay (Sigma).
To the GST-aptamer solid phases, we added either 1.5 mgo f
recombinant purified 6xHis-RasGAP SH3 or 5 mg of total protein
extract. We incubated 2 h at 4uC. We washed using lysis buffer I
five times 1 mL and four times 5 mL, respectively. We boiled the
beads in sample buffer and ran SDS-PAGE. We performed
Western blot experiments using the mAb200 RasGAP antibody.
RasGAP-AuroraB interaction. We washed three times the
transfected cells with ice-cold phosphate-buffered saline (PBS,
pH 7.4) and we lyzed them for 15 min at 4uC in 250 mL a lysis
buffer consisting of 50 mM HEPES pH 7.5, 150 mM NaCl, 1%
Triton X-100, 10% glycerol, 1 mM MgCl2, 1 mM EGTA, 1 mM
Na3VO4/10 mM NaF (phosphatase inhibitors) and a mix of
protease inhibitors (1 mM PMSF, Complete TM protease
inhibitors cocktail, Roche). We collected the lysates and
centrifuged at 13000 g for 10 min at 4uC to remove insoluble
materials. We determined protein concentrations using a Bradford
assay (Sigma). We added 300 mg proteins to 100 mL of CNBr-
activated sepharose bead slurries, uncoupled or coupled to a
p62
DOCK-derived peptide, and we incubated for 2 h at 4uC. We
washed the beads three times in Hepes 50 mM pH7.5, NaCl
150 mM, Triton 0.1%, boiled them in sample buffer and ran a
SDS-PAGE followed by a Western blot using the mAb200
RasGAP SH3 antibody (1:1000) or a rabbit polyclonal Aurora B
antibody (Abcam) (1:2500). We used as secondary antibodies anti-
rabbit or anti-mouse IgG coupled to horseradish peroxidase (GE
Healthcare) (1:10 000). We revealed the blots using a Supersignal
system (Pierce).
Determination of phosphorylated Histone H3 content
We lysed HeLa cells expressing either C6 or RG27 peptide
aptamers and we extracted soluble protein contents as described
above. We loaded 50 mg of soluble protein extracts onto a SDS-
PAGE. We performed a Western blot using either a c-tubulin
antibody (Santa Cruz Sc-7396, 1:1000) or a phospho-Serine 28
Histone H3 antibody (Abcam Ab5169, 1:1000).
Cell culture and cellular assays
Cell culture. Human cell lines HeLa, HCT116 and Panc
10.05 and normal fibroblasts (CRL 2068) were obtained from
American Type Culture Collection (Rockville, MD) and
maintained in DMEM or RPMI 1640 supplemented with 10%
heat-inactivated fetal calf serum, 2 mM glutamine, 50 mg/mL of
streptomycin, 50 mg/mL of penicillin and maintained in 5% CO2
at 37uC. We purchased media and supplements from Invitrogen.
Plasmid and siRNA transfections. For all plasmid
transfections (except for the mammalian two-hybrid assays), we
grew the cells in 6-well dishes to reach a 60% confluence. We
incubated about 3610
5 cells with 2 mg of peptide aptamer
expression plasmid and 5 mL Exgen-500 reagent (Euromedex,
France) for HeLa and HCT116 cells or 2 mL Hiperfect (Qiagen)
for Panc 10.05 cells. For plasmid/siRNA co-transfections of HeLa
cells, we plated 2610
5 cells/well in 6-well plates. 12 h after
plating, we incubated the cells with 2 mg of peptide aptamer
expression plasmid, 20 nM of siRNA duplexes and 2 mL Hiperfect
(Quiagen), according to manufacturer’s instructions.
Colony formation assays. 20 h after transfection, we
collected and plated the cells onto multiple 60-mm plates. We
cultured the cells for two weeks in presence of 0.1 mg/mL
hygromycin. We fixed and stained the cells with a 0.1% crystal
violet solution.
Trypan blue exclusion assay. We collected the transfected
cells by trypsination at different times post-transfection. We added
a trypan blue stain solution (0.4%, Gibco-Invitrogen) and we
counted the number of unlabeled, viable cells. We calculated the
relative viability as follows: relative viability (%)=(number of
viable cell in treated group/number of viable cell in control
group)6100. We counted at least 250 cells.
Propidium iodide and Annexin V labeling. At 36 or 48 h
after transfection, we labeled the cells with Annexin V and
propidium iodide according to the manufacturer’s instructions (BD
Biosciences). We analyzed the cells using a FACScalibur flow
cytometer and the CellQuest software (Becton Dickinson). To test
caspase involvement, we added or not 50 mM of Z-VAD-fmk
caspase inhibitor (R&D Systems) immediately after transfection of
HeLa cells. For a positive control, Staurosporine from
Streptomyces (Sigma), kept in a stock solution of 10 mM in
100% DMSO, was added to HeLa cells at a final concentration of
0.1 mM for 36 h.
Nuclear labeling and observation. We grew HeLa cells on
glass cover-slips. After 24 h, we transfected C6 or RG27
expression plasmid as described above. After 36 h, we fixed the
cells for 15 min in 4% paraformaldehyde diluted in PBS. We
permeabilized the cells in 0.5% Triton X-100 for 5 min, rinsed
three times with PBS, incubated in a blocking solution (3% BSA in
PBS) for 30 min, stained with DAPI diluted in blocking solution
for 3 min, and rinsed twice with PBS. We observed the nuclei
using a motorized epifluorescence microscope (Leica DM6000)
endowed with a cooled CCD camera (Hamamatsu C5985).
Caspase activity assays. We performed fluorometric
caspase activity assays on 10,000 cells by flow cytometry,
according to the instructions of the manufacturer (R&D
Systems, Abingon, UK). We detected active caspases by Western
blots using 50 mg of soluble protein extracts from HeLa cells, and
antibodies directed against active caspase 3, 8, and 9 (Biovision,
USA) according to manufacturer’s instructions. We used an
antibody directed against c-tubulin (Santa Cruz, USA) as a
loading control. We used secondary antibodies coupled to
horseradish peroxidase (GE Healthcare) and we revealed the
blots using a supersignal system (Pierce).
HeLa cell two-hybrid assay. We seeded 10
4 HeLa cells/
well in a 96 well plate. We incubated overnight in triplicate 10 ng
of pBIND-RasGAP SH3, 190 ng of pACT-aptamer, 100 ng of
pG5luc (firefly luciferase reporter plasmid, Promega), 0.5 mL
jetPEI (Qbiogene) and 9.5 mL NaCl 150 mM. We rinsed the
cells and cultured them for another 24 h. We revealed sequentially
the firefly (luc) and Renilla (ruc) luciferase activities using a Dual-Glo
kit (Promega) and an Envision plate reader (Perkin Elmer). Since
we observed no significant fluctuations in transfection rates (as
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values to quantify two-hybrid interaction phenotypes.
Acknowledgments
We thank Mathieu Gutmann for his helpful guidance for mammalian cell
two-hybrid assays. We thank Marc Le Breton for the construction of
pGEX-4T1 aptamer expression plasmids, Eric Dusserre for the construc-
tion of pEG202-Nck, Vincent Guen for his assistance in peptide aptamer
expression. We are grateful to J. Grassi (CEA) for the kind gift of the
mAb200 monoclonal antibody.
Author Contributions
Conceived and designed the experiments: FR MB CC AB YL PM MS
ALM NH OM IM CG PC. Performed the experiments: PP RHS MB CC
AB PM JS ALM NH OM SD. Analyzed the data: RHS MB CC AB YL
PM MS JS ALM NH OM IM SD PC. Wrote the paper: PP FR CG PC.
References
1. Mitin N, Rossman KL, Der CJ (2005) Signaling interplay in Ras superfamily
function. Curr Biol 15: R563–574.
2. Tocque B, Delumeau I, Parker F, Maurier F, Multon MC, et al. (1997) Ras-
GTPase activating protein (GAP): a putative effector for Ras. Cell Signal 9:
153–158.
3. Yang JY, Widmann C (2001) Antiapoptotic signaling generated by caspase-
induced cleavage of RasGAP. Mol Cell Biol 21: 5346–5358.
4. Leblanc V, Tocque B, Delumeau I (1998) Ras-GAP controls Rho-mediated
cytoskeletal reorganization through its SH3 domain. Mol Cell Biol 18:
5567–5578.
5. Leblanc V, Delumeau I, Tocque B (1999) Ras-GTPase activating protein
inhibition specifically induces apoptosis of tumour cells. Oncogene 18:
4884–4889.
6. Parker F, Maurier F, Delumeau I, Duchesne M, Faucher D, et al. (1996) A Ras-
GTPase-activating protein SH3-domain-binding protein. Mol Cell Biol 16:
2561–2569.
7. Hu KQ, Settleman J (1997) Tandem SH2 binding sites mediate the RasGAP-
RhoGAP interaction: a conformational mechanism for SH3 domain regulation.
Embo J 16: 473–483.
8. Gigoux V, L’Hoste S, Raynaud F, Camonis J, Garbay C (2002) Identification of
Aurora kinases as RasGAP Src homology 3 domain-binding proteins. J Biol
Chem 277: 23742–23746.
9. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, et al. (1996) Genetic selection
of peptide aptamers that recognize and inhibit cyclin- dependent kinase 2.
Nature 380: 548–550.
10. Hoppe-Seyler F, Crnkovic-Mertens I, Tomai E, Butz K (2004) Peptide
aptamers: specific inhibitors of protein function. Curr Mol Med 4: 529–538.
11. Baines IC, Colas P (2006) Peptide aptamers as guides for small molecule drug
discovery. Drug Disc Today 11: 334–341.
12. Bickle MBT, Dusserre E, Moncorge ´ O, Bottin H, Colas P (2006) Selection and
characterization of large collections of peptide aptamers through optimized yeast
two-hybrid procedures. Nature Protoc 1: 1066–1091.
13. Yang YS, Garbay C, Duchesne M, Cornille F, Jullian N, et al. (1994) Solution
structure of GAP SH3 domain by 1H NMR and spatial arrangement of essential
Ras signaling-involved sequence. Embo J 13: 1270–1279.
14. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, et al. (2005)
Classification of cell death: recommendations of the Nomenclature Committee
on Cell Death. Cell Death Differ 12 Suppl 2: 1463–1467.
15. Goto H, Yasui Y, Nigg EA, Inagaki M (2002) Aurora-B phosphorylates Histone
H3 at serine28 with regard to the mitotic chromosome condensation. Genes
Cells 7: 11–17.
16. Andrews PD (2005) Aurora kinases: shining lights on the therapeutic horizon?
Oncogene 24: 5005–5015.
17. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev
Cancer 3: 46–54.
18. Abed N, Bickle M, Marie B, Schapira M, Sanjuan-Espan ˜a R, et al. (2007) A
comparative analysis of perturbations caused by a gene knockout, a dominant
negative allele and a set of peptide aptamers. Mol Cell Prot 6: 2110–2121.
19. Tomai E, Butz K, Lohrey C, von Weizsacker F, Zentgraf H, et al. (2006) Peptide
aptamer-mediated inhibition of target proteins by sequestration into aggresomes.
J Biol Chem 281: 21345–21352.
20. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO,
et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the
Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262–267.
21. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, et al. (2006)
Validating Aurora B as an anti-cancer drug target. J Cell Sci 119: 3664–3775.
22. Michod D, Yang JY, Chen J, Bonny C, Widmann C (2004) A RasGAP-derived
cell permeable peptide potently enhances genotoxin-induced cytotoxicity in
tumor cells. Oncogene 23: 8971–8978.
23. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat
Rev Cancer 3: 11–22.
24. Appels NM, Beijnen JH, Schellens JH (2005) Development of farnesyl
transferase inhibitors: a review. Oncologist 10: 565–578.
25. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, et al. (2002)
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert
Ras-dependent transformation phenotypes in human cancer cells. Proc Natl
Acad Sci U S A 99: 14398–14403.
RasGAP SH3 Peptide Aptamers
PLoS ONE | www.plosone.org 12 August 2008 | Volume 3 | Issue 8 | e2902